Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 7/20 | 0.56 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969447 | 0.87 | RXFP1 (0.62) | RXFP1KMT2AMAOAMAOBCYP2C19 | |
| SCHEMBL15075367 | 0.86 | RXFP1 (0.58) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL3455609 | 0.84 | ADORA2B (0.52) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL1054300 | 0.84 | CYP2C19 (0.50) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL8664912 | 0.84 | TSHR (0.54) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL9073542 | 0.84 | RXFP1 (0.60) | RXFP1KMT2AMAOAMAOBCYP2C19 | |
| SCHEMBL28993778 | 0.84 | RXFP1 (0.59) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL28644356 | 0.84 | RXFP1 (0.59) | RXFP1KMT2AMEN1MAOAMAOB | |
| SCHEMBL19969448 | 0.84 | RXFP1 (0.59) | RXFP1KMT2AMAOAMAOBCYP2C19 | |
| SCHEMBL28061963 | 0.84 | RXFP1 (0.59) | RXFP1KMT2AMEN1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0167566-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | SUNSHINE ABRAHAM (US) | 1987-06-29 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12089621-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2002026055-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093832-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED DOSAGE REQUIREMENTS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093831-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093701-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED PH LIMITATIONS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | RXFP1 816/4885KMT2A 3923/4885MEN1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.